EP1503739A4 - Verzögerte freisetzung von guaifenesin-kombinationsprodukten - Google Patents

Verzögerte freisetzung von guaifenesin-kombinationsprodukten

Info

Publication number
EP1503739A4
EP1503739A4 EP03736462A EP03736462A EP1503739A4 EP 1503739 A4 EP1503739 A4 EP 1503739A4 EP 03736462 A EP03736462 A EP 03736462A EP 03736462 A EP03736462 A EP 03736462A EP 1503739 A4 EP1503739 A4 EP 1503739A4
Authority
EP
European Patent Office
Prior art keywords
sustained release
combination drugs
guaifenesin
guaifenesin combination
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP03736462A
Other languages
English (en)
French (fr)
Other versions
EP1503739A1 (de
Inventor
Robert D Davis
Ralph W Blume
Donald Jeffrey Keyser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reckitt Benckiser LLC
Original Assignee
Adams Respiratory Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/121,706 external-priority patent/US6955821B2/en
Priority claimed from US10/406,557 external-priority patent/US7838032B2/en
Priority claimed from US10/406,574 external-priority patent/US7985420B2/en
Application filed by Adams Respiratory Therapeutics Inc filed Critical Adams Respiratory Therapeutics Inc
Publication of EP1503739A1 publication Critical patent/EP1503739A1/de
Publication of EP1503739A4 publication Critical patent/EP1503739A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03736462A 2002-04-15 2003-04-15 Verzögerte freisetzung von guaifenesin-kombinationsprodukten Ceased EP1503739A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US121706 1998-07-24
US10/121,706 US6955821B2 (en) 2000-04-28 2002-04-15 Sustained release formulations of guaifenesin and additional drug ingredients
US406574 2003-04-04
US10/406,557 US7838032B2 (en) 2000-04-28 2003-04-04 Sustained release of guaifenesin
US10/406,574 US7985420B2 (en) 2000-04-28 2003-04-04 Sustained release of guaifenesin combination drugs
US406557 2003-04-04
PCT/US2003/011500 WO2003088952A1 (en) 2002-04-15 2003-04-15 Sustained release of guaifenesin combination drugs

Publications (2)

Publication Number Publication Date
EP1503739A1 EP1503739A1 (de) 2005-02-09
EP1503739A4 true EP1503739A4 (de) 2006-06-21

Family

ID=29255202

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03736462A Ceased EP1503739A4 (de) 2002-04-15 2003-04-15 Verzögerte freisetzung von guaifenesin-kombinationsprodukten

Country Status (10)

Country Link
EP (1) EP1503739A4 (de)
JP (1) JP5466346B2 (de)
CN (1) CN1655766B (de)
AU (1) AU2003237807B2 (de)
CA (1) CA2481739C (de)
EA (1) EA007156B1 (de)
IL (1) IL164438A0 (de)
MX (1) MXPA04010225A (de)
WO (1) WO2003088952A1 (de)
ZA (1) ZA200409171B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
KR20060076319A (ko) * 2003-09-24 2006-07-04 콤비네이토릭스, 인코포레이티드 약물 조합들을 투여하는 치료 요법
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
NZ553587A (en) * 2004-08-13 2010-12-24 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmacutically acceptable salt thereof
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
CN1994285B (zh) * 2006-01-04 2011-03-16 上海医药工业研究院 愈创木酚甘油醚缓释微丸及其制备方法
US20080176955A1 (en) * 2007-01-16 2008-07-24 Victory Pharma, Inc. Combined administration of benzonatate and guaifenesin
CN101658507B (zh) * 2008-08-26 2011-12-07 北京科信必成医药科技发展有限公司 一种愈创木酚甘油醚和伪麻黄碱的复方缓释制剂
SG173528A1 (en) 2009-02-04 2011-09-29 Astellas Pharma Inc Pharmaceutical composition for oral administration
EP3354652B1 (de) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidin-derivate als jak1-inhibitoren
US9339478B2 (en) 2011-02-04 2016-05-17 Reckitt Benckiser Llc Pharmaceutical formulation
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CN102755304A (zh) * 2012-08-03 2012-10-31 四川百利药业有限责任公司 一种愈美胶囊的制备方法
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
CN105982860B (zh) * 2015-02-11 2020-04-14 北京科信必成医药科技发展有限公司 愈创甘油醚无水吞服掩味颗粒
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
EP0384514A2 (de) * 1989-02-21 1990-08-29 Norwich Eaton Pharmaceuticals, Inc. Tablette mit Doppelwirkung
WO2000033818A1 (en) * 1998-12-11 2000-06-15 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
WO2001019901A2 (en) * 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
US20020022058A1 (en) * 2000-07-08 2002-02-21 Lovercheck Dale R. Unit dose of material in system and method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372525B1 (en) * 1999-12-20 2002-04-16 Taiwan Semiconductor Manufacturing Company Wafer-level antenna effect detection pattern for VLSI
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552899A (en) * 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4552899B1 (de) * 1984-04-09 1992-10-20 Analgesic Associates
EP0384514A2 (de) * 1989-02-21 1990-08-29 Norwich Eaton Pharmaceuticals, Inc. Tablette mit Doppelwirkung
WO2000033818A1 (en) * 1998-12-11 2000-06-15 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
WO2001019901A2 (en) * 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
US20020022058A1 (en) * 2000-07-08 2002-02-21 Lovercheck Dale R. Unit dose of material in system and method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO03088952A1 *

Also Published As

Publication number Publication date
AU2003237807B2 (en) 2008-10-23
CA2481739A1 (en) 2003-10-30
EA200401369A1 (ru) 2005-06-30
EA007156B1 (ru) 2006-08-25
EP1503739A1 (de) 2005-02-09
WO2003088952A1 (en) 2003-10-30
MXPA04010225A (es) 2005-07-05
CA2481739C (en) 2012-10-02
JP2005528402A (ja) 2005-09-22
IL164438A0 (en) 2005-12-18
CN1655766B (zh) 2012-05-30
JP5466346B2 (ja) 2014-04-09
AU2003237807A1 (en) 2003-11-03
ZA200409171B (en) 2005-07-27
CN1655766A (zh) 2005-08-17

Similar Documents

Publication Publication Date Title
IL236190A0 (en) Controlled release of anti-infections
IL164438A0 (en) Sustaubed release of guaifenesin combination drugs
EP1549296A4 (de) Metformin-formulierungen mit verzögerter freisetzung
EP1581236A3 (de) Verzögerte freisetzung von anti-infektionsmitteln
IL173866A0 (en) Sustained release dosage forms of ziprasidone
EP1793803A4 (de) Einfach implantierbare wirkstoffzusammensetzungen mit verzögerter freisetzung
PL373914A1 (en) Immediate release dosage forms containing solid drug dispersions
EP1551402A4 (de) Gegen missbrauch gesicherte pharmazeutische zusammensetzungen
EP1469840A4 (de) Cyclosporin-enthaltende pharmazeutische zusammensetzung mit verzögerter freisetzung
AU2003260803A8 (en) Sustained release pharmaceutical composition
IL166424A0 (en) Sustained release formulations comprising lamotigine
IL174958A0 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
EG24479A (en) Modified release pharmaceutical formulation
AU2003284634A1 (en) Sustained release drug carrier
PL377495A1 (pl) Stały lek do stosowania doustnego
PL373328A1 (en) Sustained release pharmaceutical prepartations and methods for producing the same
PL376840A1 (pl) Kompozycja farmaceutyczna o przedłużonym uwalnianiu
AU2003241671A8 (en) Controlled-release drug composition
IL176222A0 (en) Sustained release torsemide dosage forms
GB0202900D0 (en) Novel formulations of drugs
EP1802346A4 (de) Pharmazeutische zusammensetzung mit verzögerter freisetzung
GB0119848D0 (en) Delayed and sustained drug release
IL164077A0 (en) Sustained release formulation of tramadol
EP1501844A4 (de) Disaccharide für die arzneimittelentwicklung
GB2401043B (en) Drug

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041029

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1072906

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ADAMS RESPIRATORY THERAPEUTICS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20060523

17Q First examination report despatched

Effective date: 20071031

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RECKITT, BENCKISER, INC.

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RECKITT BENCKISER LLC

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1072906

Country of ref document: HK

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20150126